Korea Stock Market Insights

Tag: Pharmaceuticals

  • Kwangdong Pharmaceutical Secures 4-Year Samdasoo Contract: A Boost for Revenue and Investment?

    Kwangdong Pharmaceutical Secures 4-Year Samdasoo Contract: A Boost for Revenue and Investment? 대표 차트 이미지

    1. What Happened? : 4-Year Samdasoo Distribution Contract Secured

    On September 25, 2025, Kwangdong Pharmaceutical finalized a ‘Jeju Samdasoo Domestic Distribution Contract (excluding Jeju Island)’ with Jeju Special Self-Governing Province Development Corporation. This 4-year agreement, effective from January 1, 2026, to December 31, 2029, grants Kwangdong exclusive distribution rights for Samdasoo across South Korea (excluding Jeju Island). This represents approximately 19.5% of Kwangdong’s 2024 consolidated revenue, totaling ₩319.7 billion.

    2. Why Does it Matter? : Stabilizing a Shaky Performance

    Kwangdong experienced declining sales and a sharp drop in operating profit in the first half of 2025, primarily due to decreased Gardasil sales and increased fixed costs. The Samdasoo renewal is crucial as it provides a stable revenue base for the next four years, paving the way for earnings recovery. This stabilization of the F&B segment strengthens the financial foundation for investments in pharmaceuticals and new business ventures.

    3. So What’s Next? : Enhanced Financial Stability, Potential Stock Price Increase

    In the short term, the contract is expected to boost investor sentiment and drive stock price appreciation. In the long term, the stable cash flow generated by the Samdasoo distribution can contribute to R&D investment and new business expansion, potentially increasing the company’s overall value.

    • Positives: Revenue stabilization, strengthened business portfolio, increased predictability
    • Neutral/Potential Impacts: Contract profitability, competitive landscape

    4. What Should Investors Do? : Buy Rating, Monitor Key Variables

    The investment recommendation is ‘Buy’, based on the secured revenue stream, low valuation, and potential for long-term growth. However, investors should closely monitor key variables such as the specific profitability of the Samdasoo contract, F&B new product development, pharmaceutical segment recovery, performance of the solar energy business, and fluctuations in interest rates and exchange rates.

    Frequently Asked Questions

    How will the Samdasoo renewal impact Kwangdong’s earnings?

    Securing approximately ₩319.7 billion in stable revenue over four years is expected to offset the sluggish performance of the first half of 2025 and positively impact future earnings.

    What is the outlook for Kwangdong Pharmaceutical’s stock price?

    Short-term gains are anticipated due to improved investor sentiment. Long-term, the stable cash flow could drive enterprise value growth. However, it’s crucial to monitor contract profitability and the performance of other business segments.

    What should investors consider when evaluating Kwangdong Pharmaceutical?

    Key considerations include the specific terms and profitability of the Samdasoo contract, competitive dynamics in the F&B sector, the recovery of the pharmaceutical segment, the success of the solar energy business, and macroeconomic conditions.

    Kwangdong Pharmaceutical Secures 4-Year Samdasoo Contract: A Boost for Revenue and Investment? 관련 이미지
    Kwangdong Pharmaceutical Secures 4-Year Samdasoo Contract: A Boost for Revenue and Investment? 관련 이미지

  • Kolmar Korea IR Analysis: Investment Strategies and Future Outlook


    Kolmar Korea IR Analysis: Investment Strategies and Future Outlook 대표 차트 이미지



    What Happened?

    Kolmar Korea held an IR session on September 25, 2025, at the Daishin Cosmetic Corporate Day. The company presented its key business performance and answered investor questions. This IR played a crucial role in enhancing transparency and strengthening communication with investors.

    Key Takeaways from the IR Session

    Kolmar Korea’s core business is cosmetics ODM, but it is diversifying its portfolio into pharmaceuticals, packaging, and H&B. Recent strategic moves include the acquisition of Kolmar UX and expansion into solar power. The IR session highlighted these diversification strategies, R&D investments, and future growth plans.

    Market Outlook and Investment Strategies

    The investment outlook for Kolmar Korea remains neutral following the IR session. While short-term stock price volatility is possible depending on market reactions, the company’s fundamentals are expected to remain stable. Long-term growth potential exists based on its solid business foundation and R&D capabilities, but investors should consider risks like the changing global economic environment and intensifying competition. Careful analysis of the IR session details, particularly information regarding new growth engines, overseas strategies, and ESG management plans, is crucial for informed investment decisions. Continuous monitoring of macroeconomic factors and industry competition is also recommended.



    Frequently Asked Questions (FAQ)

    What are Kolmar Korea’s main businesses?

    Kolmar Korea operates in cosmetics, pharmaceuticals, and packaging. Its core business is cosmetics ODM (Original Design Manufacturing).

    How has Kolmar Korea been performing recently?

    As of the first half of 2025, sales and operating profit increased year-on-year, with improved operating profit margin. However, the rising trend in consolidated debt-to-equity ratio requires attention.

    What should investors consider when investing in Kolmar Korea?

    Key risk factors include intensifying competition, exchange rate volatility, and raw material price fluctuations. The potential financial burden from aggressive M&A strategies should also be considered.



    Kolmar Korea IR Analysis: Investment Strategies and Future Outlook 관련 이미지


  • Celltrion Acquires US Biopharma for $4.6 Billion: Accelerating Global Pharma Ambitions

    Celltrion Acquires US Biopharma for $4.6 Billion: Accelerating Global Pharma Ambitions 대표 차트 이미지

    1. What Happened? : Celltrion Acquires 100% of Imclone Systems LLC

    On September 23, 2025, Celltrion announced the acquisition of 100% of Imclone Systems LLC, a US-based biopharmaceutical company, for $4.6 billion. The acquisition was executed through Celltrion USA.

    2. Why the Acquisition? : Direct US Market Entry and Enhanced Production

    This acquisition represents Celltrion’s strategic move to penetrate the US market. By securing a local production base, Celltrion aims to reduce production costs, stabilize supply chains, and strengthen collaboration with the FDA. This is expected to be particularly beneficial for the successful launch of new drugs like Remsima SC and Yuflyma in the US market.

    3. What’s Next? : Celltrion’s Evolution into a Global Pharmaceutical Player

    This acquisition positions Celltrion to evolve beyond a biosimilar company into a global pharmaceutical player. Backed by a robust financial structure, this investment is projected to positively impact long-term growth. However, potential risks include post-merger integration challenges, validation of the acquired company’s business, and currency fluctuations.

    4. What Should Investors Do? : Explore Investment Opportunities from a Long-Term Perspective

    Experts view this acquisition as a positive event, strengthening Celltrion’s long-term growth potential. Investors should closely monitor the post-merger integration process, the performance of Imclone Systems LLC, and Celltrion’s key product sales in the US market, adopting a long-term investment strategy.

    Why is this acquisition important for Celltrion?

    This acquisition is crucial for Celltrion’s direct entry into the US market and strengthening its production competitiveness. Securing a local production facility enables cost reduction, supply chain stabilization, and enhanced collaboration with the FDA.

    What are the prospects for Celltrion after the acquisition?

    The outlook is positive. This acquisition is seen as a stepping stone for Celltrion to become a global pharmaceutical company. However, it is essential to consider potential risks such as post-merger integration challenges and validation of the acquired company’s business.

    What should investors pay attention to?

    Investors should closely monitor the post-merger integration process, the performance of Imclone Systems LLC, and Celltrion’s key product sales in the US market. External factors such as fluctuations in exchange rates and interest rates should also be considered.

    Celltrion Acquires US Biopharma for $4.6 Billion: Accelerating Global Pharma Ambitions 관련 이미지

  • Kolmar Korea IR Analysis: 2025 Growth Momentum and Investment Strategy

    Kolmar Korea IR Analysis: 2025 Growth Momentum and Investment Strategy 대표 차트 이미지

    1. Kolmar Korea IR Event: What Happened?

    Kolmar Korea presented its current business status and future vision at an IR event held at the Kiwoom Corporate Day on September 18, 2025. Following the release of positive first-half results, investor interest in the event was high.

    2. Solid Fundamentals: Why Pay Attention?

    According to the 2025 semi-annual report, Kolmar Korea showed stable growth in cosmetics ODM, packaging, pharmaceuticals, and H&B business segments. The steady performance of the cosmetics business and the growth of HK innoN’s pharmaceutical business were particularly noteworthy. Achieving sales of KRW 1.3839 trillion and operating profit of KRW 133.4 billion, the company improved profitability and maintained sound financial health.

    • Cosmetics: Continued growth through innovative R&D and response to vegan/derma cosmetics market
    • Packaging: Expected synergy through Yeonwoo’s design and eco-friendly technology
    • Pharmaceuticals: ‘K-CAB’ centered portfolio and securing a new drug pipeline
    • H&B: Diversification of portfolio in line with changes in the health functional food/beverage market trends

    3. Impact of the IR Event and Investment Strategy

    This IR event is expected to have a positive impact on corporate value reassessment and investor confidence. However, as uncertainties in macroeconomic variables exist, investors should make cautious investment decisions by comprehensively considering the IR presentation content and market conditions.

    4. Action Plan for Investors

    Carefully analyze IR materials and understand the company’s future strategies through the management’s presentation. It’s also crucial to review the company’s strategies for responding to macroeconomic volatility, such as fluctuations in exchange rates, interest rates, and oil prices, and incorporate this understanding into your investment decisions.

    Q: What are Kolmar Korea’s main business segments?

    A: Kolmar Korea operates in cosmetics ODM, packaging, pharmaceuticals, and H&B businesses.

    Q: How was Kolmar Korea’s performance in the first half of 2025?

    A: The company achieved KRW 1.3839 trillion in sales and KRW 133.4 billion in operating profit, showing growth compared to the same period last year.

    Q: What were the main topics of this IR event?

    A: The main topics included the current business status, growth strategy, future vision presentation, and Q&A session.

    Kolmar Korea IR Analysis: 2025 Growth Momentum and Investment Strategy 관련 이미지
    Kolmar Korea IR Analysis: 2025 Growth Momentum and Investment Strategy 관련 이미지

  • SK Biopharmaceuticals Stock Forecast After September 16th Announcement: Key Analysis & Investment Strategies





    1. What Happened?: September 16th Announcement Analysis

    SK Biopharmaceuticals released a ‘Matters Regarding Investment Decisions’ announcement on September 16th. While specific details are yet to be disclosed, it potentially relates to M&A, large-scale investments, or new business ventures.

    2. Why It Matters: Potential Impact Analysis

    • Positive Scenario: Investment in new pipelines, technology acquisition, or business expansion could drive long-term enterprise value growth.
    • Negative Scenario: Large-scale investments could increase debt, while negative market interpretations could lead to short-term stock volatility.

    A thorough analysis of the business and financial impacts is crucial following the release of the full announcement details.

    3. Understanding SK Biopharmaceuticals: Fundamentals and Business Competitiveness

    • Solid Fundamentals: KRW 320.7 billion in revenue for H1 2025 (29.5% YoY growth), KRW 87.5 billion operating profit, successful turnaround to profitability.
    • Cenobamate-Driven Growth: Accounts for 95.1% of revenue, expanding in US and European markets.
    • New Business Expansion: Entry into RPT and TPD sectors, adoption of AI-based drug discovery platform.

    4. The Market Context: Macroeconomic Environment Analysis

    • Exchange Rate Volatility: Fluctuations in KRW/USD exchange rate could impact profitability.
    • Interest Rate Cuts: Potential for reduced fundraising costs.
    • Oil Price Decline: Potential for lower transportation and raw material procurement costs.

    5. Investor Action Plan

    • Analyze Announcement Details: Adjust investment strategies based on the specifics of the announcement.
    • Maintain a Long-Term Perspective: Invest in pharmaceutical companies with a long-term view, considering the inherent uncertainties of drug development.
    • Risk Management: Consider macroeconomic variables such as exchange rate and interest rate fluctuations.


    FAQ

    What are the key details of the September 16th announcement?

    The precise details are currently undisclosed. It’s anticipated to pertain to M&A, substantial investments, or new business ventures. We will provide updates as further information becomes available.

    What are SK Biopharmaceuticals’ core businesses?

    SK Biopharmaceuticals primarily focuses on the development and sale of treatments for central nervous system (CNS) diseases, centered around its epilepsy drug, Cenobamate. They are also expanding into new business areas like RPT and TPD.

    What are the key considerations when investing in SK Biopharmaceuticals?

    Investors should consider the inherent uncertainties of drug development, the impact of macroeconomic factors like exchange rate and interest rate fluctuations, and the increasingly competitive landscape. Thorough research and analysis are crucial before making investment decisions.



  • HLBpep’s Jangseong Plant Suspension: What Investors Need to Know



    HLBpep's Jangseong Plant Suspension: What Investors Need to Know 대표 차트 이미지






    HLBpep’s Jangseong Plant Suspension: What Happened?

    HLBpep’s Jangseong plant has received a one-month suspension order starting September 25, 2025, related to the manufacturing of desmopressin acetate and leuprorelin acetate. This represents approximately 21.59% of HLBpep’s sales, equivalent to 1.3 billion KRW.

    Why is the Suspension Significant?

    HLBpep is already in a capital impairment state and urgently needs to improve its financial health. This suspension could negatively impact not only short-term sales but also the company’s image and investor confidence. The affected products represent a significant portion of their pharmaceutical peptide sales, suggesting a substantial revenue hit.

    Investment Strategies in Light of the Suspension

    • Understand the Cause and Preventive Measures: Carefully review the reasons for the suspension, HLBpep’s response, and their plans to prevent recurrence.
    • Reassess Revenue Impact: Re-evaluate the revenue contribution of the affected products and analyze the financial impact on HLBpep.
    • Prepare for Volatility: Be prepared for potential short-term stock price volatility and develop a strategy for market downturns.
    • Maintain a Long-Term Perspective: Consider HLBpep’s pipeline development, financial recovery efforts, and competitiveness in the peptide business when maintaining a long-term investment view.
    • Monitor Market Conditions: Continuously monitor macroeconomic factors such as interest rates and exchange rates and their potential impact on HLBpep.

    Key Action Plan for Investors

    • Gather Information: Collect accurate information through company announcements, news reports, and analyst reports.
    • Analyze Financial Statements: Thoroughly analyze HLBpep’s financial statements and identify risk factors.
    • Consult with Experts: Consider seeking advice from investment professionals to inform your investment decisions.


    FAQ

    What is the HLBpep Jangseong plant suspension?

    It’s a one-month administrative order halting manufacturing operations at HLBpep’s Jangseong plant related to the production of desmopressin acetate and leuprorelin acetate.

    How long is the suspension?

    The suspension is for one month, from September 25, 2025, to October 24, 2025.

    How will this suspension impact HLBpep?

    It is expected to negatively impact HLBpep through short-term sales decline, damage to the company’s image, and negative investor sentiment.

    How should investors respond?

    Investors should understand the reasons for the suspension and the company’s response, reassess the revenue impact, and prepare for potential stock price volatility. Maintaining a long-term perspective and monitoring market conditions is also crucial.









    HLBpep's Jangseong Plant Suspension: What Investors Need to Know 관련 이미지
    HLBpep's Jangseong Plant Suspension: What Investors Need to Know 관련 이미지




  • Kolmar Korea IR Analysis: Q2 2025 Earnings and Stock Outlook



    Kolmar Korea IR Analysis: Q2 2025 Earnings and Stock Outlook 대표 차트 이미지






    What Happened? Kolmar Korea’s Q2 Earnings IR

    Kolmar Korea held an investor relations (IR) meeting on September 16, 2025, to present its Q2 2025 earnings and discuss key management updates. The IR included a presentation on the company’s performance for the first half of 2025, followed by a Q&A session with investors.

    Why is it Important? Analyzing Kolmar Korea’s Fundamentals and Growth Potential

    Kolmar Korea maintains strong fundamentals, driven by its robust cosmetics ODM business and the growth of its pharmaceuticals and H&B segments. The enhanced competitiveness of Yeonwoo’s packaging business and ESG management efforts also contribute positively. As of H1 2025, the company reported revenue of KRW 1.38 trillion, up 11.9% year-on-year, and operating profit of KRW 133.4 billion, up 37.6% year-on-year, indicating positive performance trends.

    What are the Outcomes and Future Outlook? Analyzing the Short-Term and Long-Term Impact

    • Short-Term Impact: Stock price volatility is expected depending on the announced Q2 earnings and future growth momentum. Positive results exceeding market expectations could lead to a stock price increase, while the opposite could exert downward pressure.
    • Long-Term Impact: Investor confidence in the company’s management strategies, new growth drivers, and risk management plans will influence the long-term stock performance. The company’s strategy to address exchange rate volatility and global economic uncertainty, along with its ability to maintain core business competitiveness and leverage synergy within its business portfolio, will be key factors.

    What Should Investors Do? Key Investment Points and Action Plan

    Investors should carefully analyze the IR presentation and consider the company’s business competitiveness, financial soundness, and ability to adapt to changes in the macroeconomic environment when making investment decisions. Focus should be placed not only on the reported figures but also on the company’s future growth strategy and plans to address risk factors.



    Frequently Asked Questions

    What are Kolmar Korea’s main businesses?

    Kolmar Korea operates in cosmetics ODM, pharmaceuticals, H&B, and packaging.

    What were the key takeaways from this IR?

    The key takeaways were the announcement of Q2 2025 earnings, key management updates, and a Q&A session with investors.

    How will the IR results affect the stock price?

    The results, along with future growth strategies and plans to address risk factors, can positively or negatively impact the stock price.









    Kolmar Korea IR Analysis: Q2 2025 Earnings and Stock Outlook 관련 이미지
    Kolmar Korea IR Analysis: Q2 2025 Earnings and Stock Outlook 관련 이미지




  • Samsung Biologics After-Hours Trading Analysis: Unveiling Hidden Meanings and Investment Strategies

    1. What Happened?: After-Hours Trading Analysis

    On September 11, 2025, a large block trade of 13,330 shares, totaling ₩13.8 billion, occurred during after-hours trading. Both buyers and sellers were foreign investors, with the selling amount slightly exceeding the buying amount. While the transaction size is small relative to the market capitalization, the movements of foreign investors warrant attention.

    2. Why It Matters: Business Report Amendment Analysis

    Samsung Biologics recently amended its business report, clarifying the calculation method for contract amounts in single sales and supply contracts, and providing further details on the minimum purchase guarantee. By emphasizing the client’s obligation to pay for the minimum purchase quantity, the company highlighted the stability of the contract. This is a positive signal, enhancing revenue stability and predictability.

    3. What’s Next?: Market Outlook and Investment Strategies

    The short-term impact of the after-hours trading itself is expected to be limited. However, the continued interest of foreign investors and the reinforced contract stability highlighted in the amended business report are expected to be positive factors in the medium to long term. However, investors should pay attention to changes in the macroeconomic environment, such as exchange rate fluctuations and potential increases in raw material prices.

    4. Investor Action Plan

    • • Continuously monitor foreign investor trading trends
    • • Carefully observe changes in the macroeconomic environment
    • • Track news related to Samsung Biologics’ fundamentals, including new contract wins and pipeline performance
    How will the after-hours trading impact Samsung Biologics’ stock price?

    The short-term impact is expected to be limited, but the movements of foreign investors are worth noting.

    What are the key takeaways from the amended business report?

    It clarified the contract amount calculation method and emphasized the customer’s payment obligation for the minimum purchase quantity, highlighting the stability of the contract.

    What should investors consider when investing in Samsung Biologics?

    Investors should continuously monitor foreign investment trends, macroeconomic changes, and news related to the company’s fundamentals.

  • Kolmar Korea IR Analysis: Q2 2025 Earnings and Investment Strategy



    Kolmar Korea IR Analysis: Q2 2025 Earnings and Investment Strategy 대표 차트 이미지






    Key Takeaways from the HSBC Virtual Series: K-Beauty Enablers

    Kolmar Korea participated in the HSBC Virtual Series: K-Beauty Enablers event and held its IR on September 12, 2025. The IR included the announcement of Q2 2025 earnings, an overview of key management updates, and a Q&A session with investors.

    Kolmar Korea’s Business Overview: Cosmetics, Pharmaceuticals, Packaging, and the Future

    Kolmar Korea’s core business is cosmetics ODM/OEM, with a diversified portfolio including pharmaceuticals (HK inno.N) and cosmetics packaging (Yeonwoo). The company maintained stable growth and continued business expansion in the first half of 2025. The cosmetics division is strengthening its competitiveness through green technology, AI skin diagnosis technology development, and ESG management. HK inno.N is focusing on the global expansion of ‘K-CAB’ and securing a new drug pipeline, while Yeonwoo is strengthening its eco-friendly materials and design competitiveness.

    Kolmar Korea’s Q2 Earnings and Key Investment Points

    Market attention is focused on the Q2 earnings announced during the IR. The company recorded sales of KRW 138.393 billion and operating profit of KRW 133.417 billion in the first half, showing a growth trend expected to continue in the second half. Investors should also pay attention to the synergy effects from new investments, such as the 100% acquisition of Kolmar UX Co., Ltd. (KRW 7.267 billion). However, the increasing debt trend due to business expansion can act as a potential risk.

    Investing in Kolmar Korea: A Strategic Analysis

    Investment decisions should be made by comprehensively considering the IR announcement, the company’s fundamentals, and external environmental factors. In the short term, a cautious approach is needed as stock price volatility may increase depending on the IR announcement. In the medium to long term, continuous growth is expected through diversification of the business portfolio, technological innovation, and strengthening ESG management. However, investors should consider external factors such as macroeconomic uncertainty, interest rate and exchange rate volatility, raw material price fluctuations, and the financial risk of increasing debt. Pay particular attention to HK inno.N’s new drug development progress and Yeonwoo’s overseas market expansion strategy when developing an investment strategy.



    Frequently Asked Questions

    What are Kolmar Korea’s main businesses?

    Kolmar Korea operates cosmetics ODM/OEM, pharmaceuticals (HK inno.N), and cosmetics packaging (Yeonwoo).

    What are the key takeaways from this IR?

    The key takeaways include the Q2 2025 earnings announcement, key management updates, and a Q&A session with investors.

    What should investors be aware of when investing in Kolmar Korea?

    Investors should consider factors such as increasing debt due to business expansion, macroeconomic uncertainty, and interest rate and exchange rate volatility.









    Kolmar Korea IR Analysis: Q2 2025 Earnings and Investment Strategy 관련 이미지
    Kolmar Korea IR Analysis: Q2 2025 Earnings and Investment Strategy 관련 이미지




  • Kolmar Korea Q2 2025 Earnings Call: Unpacking the Investment Opportunity



    Kolmar Korea Q2 2025 Earnings Call: Unpacking the Investment Opportunity 대표 차트 이미지






    What Happened? Kolmar Korea’s Q2 Earnings Call

    Kolmar Korea will host its Q2 2025 earnings call on September 8th, sharing its financial results and key management updates. Investors anticipate gaining valuable insights into the company’s growth strategies and future vision.

    Why It Matters: The Importance of the Earnings Call

    This earnings call is more than just a presentation of financial figures; it’s a vital platform for enhancing communication with investors and ensuring an accurate valuation of the company. Given the current macroeconomic uncertainties, Kolmar Korea’s response strategies and future growth drivers require clear articulation.

    Key Analysis: What to Expect

    • Fundamentals: Continued growth in the cosmetics ODM business, the growth potential of pharmaceuticals (especially ‘K-Cab’), and stable revenue generation from the packaging business are positive factors. However, intensifying competition and exchange rate volatility pose potential risks.
    • Market Expectations: The market anticipates solid Q2 results and clear communication regarding future growth prospects. The disclosure of specific information on new drug pipeline achievements and new growth engine strategies will be critical.
    • Potential Impact: Positive results and future outlook could drive stock price momentum. Conversely, disappointing performance or uncertain management strategies could exert downward pressure on the stock.

    Action Plan for Investors

    Investors should closely examine the specific details of the Q2 results, exchange rate volatility response strategies, plans for securing new growth drivers, and the outlook on macroeconomic uncertainties. Based on this information, investors should adjust their investment strategies and prepare for future stock price volatility.



    Frequently Asked Questions (FAQ)

    What are Kolmar Korea’s main business areas?

    Kolmar Korea operates in three main business segments: cosmetics ODM, pharmaceuticals, and packaging. They hold a leading position in the cosmetics ODM market, and their pharmaceutical segment, driven by subsidiary HK inno.N, is a key growth driver.

    What are the key points to watch for in this earnings call?

    Key areas of focus include Q2 results, exchange rate volatility response strategies, plans for new growth drivers, and the outlook on macroeconomic uncertainties. Specifically, detailed explanations regarding the progress of HK inno.N’s new drug development and global market entry strategy will be important.

    What are the key considerations for investing in Kolmar Korea?

    Investors should be aware of potential risks such as intensifying competition, exchange rate volatility, and macroeconomic uncertainties. Investment decisions should be made carefully after considering the information presented in the earnings call and the overall market conditions.









    Kolmar Korea Q2 2025 Earnings Call: Unpacking the Investment Opportunity 관련 이미지
    Kolmar Korea Q2 2025 Earnings Call: Unpacking the Investment Opportunity 관련 이미지